How should chlorpromazine (Thorazine) be dosed for an adult, including oral and intramuscular routes and adjustments for elderly or patients with hepatic or renal impairment?

Chlorpromazine (Thorazine) Dosing

For adults with psychotic disorders requiring acute management, start with 25 mg intramuscularly (IM), which can be repeated with an additional 25-50 mg in one hour if needed, then gradually increase over several days up to 400 mg every 4-6 hours in severe cases until the patient is controlled. 1

Route-Specific Dosing

Intramuscular (IM) Administration

Psychotic Disorders - Acute Management:

• Initial dose: 25 mg IM 1
• Repeat dosing: Additional 25-50 mg in 1 hour if necessary 1
• Titration: Gradually increase subsequent doses over several days 1
• Severe cases: Up to 400 mg every 4-6 hours until patient controlled 1
• Typical control timeframe: Most patients become quiet and cooperative within 24-48 hours, at which point switch to oral dosing 1

Nausea/Vomiting:

• Initial: 25 mg IM 1
• Maintenance: 25-50 mg every 3-4 hours as needed (if no hypotension occurs) 1

Delirium Management (Palliative Care Context):

• Starting dose: 12.5-25 mg orally or rectally stat 2
• Scheduled dosing: Every 6-12 hours if required 2
• Alternative: Can be given as slow IV (diluted) or deep IM injection 2

Intravenous (IV) Administration

Critical: IV route is ONLY for severe hiccups, surgery, and tetanus 1. AVOID injecting undiluted chlorpromazine directly into vein 1.

During Surgery:

• Dose: 2 mg per fractional injection at 2-minute intervals 1
• Maximum: Do not exceed 25 mg 1
• Dilution required: Dilute to 1 mg/mL (1 mL of 25 mg mixed with 24 mL saline) 1

Intractable Hiccups:

• Slow IV infusion: 25-50 mg in 500-1000 mL saline 1
• Patient positioning: Keep patient flat in bed 1
• Monitoring: Follow blood pressure closely 1

Oral Administration

Delirium (Palliative Care):

• Starting dose: 12.5-25 mg orally or per rectum stat 2, 3
• Scheduled: Every 6-12 hours if needed 2

Special Population Adjustments

Elderly Patients

Dosages in the lower range are sufficient for most elderly patients 1. This population is more susceptible to hypotension and neuromuscular reactions 1.

• Delirium management: Use doses in the lower range (12.5 mg rather than 25 mg) 2
• Titration: Increase dosage more gradually 1
• Monitoring: Observe closely for hypotension and extrapyramidal symptoms 1

The elderly should be considered as renally insufficient patients given the progressive decline in kidney function with age 4.

Hepatic Impairment

Use with caution in patients with hepatic impairment 2. Chlorpromazine undergoes extensive hepatic metabolism 5, and accumulation can occur with hepatic dysfunction 6.

• Recommendation: Start at lower end of dosing range
• Monitoring: Observe carefully for adverse effects including orthostatic hypotension and anticholinergic effects 2

Renal Impairment

Use with caution in patients with renal impairment 2. While chlorpromazine is primarily hepatically metabolized, metabolites may accumulate 5.

• Recommendation: Start at lower end of dosing range
• Monitoring: Watch for accumulation of metabolites and increased adverse effects

Key Safety Considerations

Administration Technique

• IM injection: Inject slowly, deep into upper outer quadrant of buttock 1
• Post-injection: Keep patient lying down for at least 30 minutes after injection due to hypotensive effects 1
• Dilution for irritation: If irritation is a problem, dilute with saline or 2% procaine 1
• Avoid subcutaneous: Subcutaneous injection is not advised 1

Common Adverse Effects

The evidence shows chlorpromazine carries significant risks 2, 3:

• Sedating and anticholinergic effects 2
• Extrapyramidal symptoms (EPSEs) 2
• Orthostatic hypotension 2, 3
• QTc prolongation 2
• Paradoxical agitation 3
• Local irritation with parenteral use 2

Critical Warnings

Avoid in patients with:

• Parkinson's disease or dementia with Lewy bodies (due to EPSE risk, though this is more emphasized for haloperidol) 7
• Severe cardiovascular disease requiring careful monitoring 3

Drug interactions: Be aware of potential interactions with other CNS depressants, anticholinergic agents, and medications affecting QTc interval 2.

Dosing Context and Evidence Quality

The dosing recommendations come primarily from FDA labeling 1 and palliative care guidelines 2, 3. The 2018 ESMO guidelines provide the most recent high-quality guidance for delirium management in cancer patients 2, while the FDA label provides comprehensive dosing across multiple indications 1.

Important limitation: Despite over 60 years of chlorpromazine use, high-quality dose-response studies are lacking 8. A 2017 Cochrane review found only moderate-quality evidence comparing different dose ranges, with most studies being hospital-based trials of less than six months duration 8. The shift toward lower doses (≤400 mg/day) has occurred through clinical experience rather than rigorous trial evidence 8.

Pharmacokinetic considerations: Chlorpromazine exhibits high between-subject variability in half-life (mean 11 hours), volume of distribution, and clearance 5. Oral bioavailability is very low (4-38%) and dose-dependent due to extensive first-pass metabolism 5. This variability underscores the importance of individualized dose titration and close monitoring.